Ulcerative keratitis is a serious inflammatory condition affecting the cornea that requires urgent medical attention and a carefully planned treatment strategy to protect vision and, in some cases, address life-threatening underlying diseases.

Understanding Treatment Goals for This Serious Eye Condition

When someone develops ulcerative keratitis, especially the form known as peripheral ulcerative keratitis (a condition affecting the edge of the cornea near the colored part of the eye), treatment focuses on several critical goals. The primary aim is to stop the progression of corneal damage and prevent perforation—a medical emergency where the cornea develops a hole. Doctors also work to control inflammation, manage pain, preserve or restore vision, and address any underlying health conditions that may be driving the disease.^[1][2]

Treatment approaches depend heavily on what is causing the ulceration. When the condition stems from an autoimmune process—where the body’s immune system mistakenly attacks its own tissues—the treatment strategy differs significantly from cases caused by infection. The stage of disease progression, the depth and location of corneal thinning, and whether other parts of the eye are affected all influence treatment decisions. Additionally, if a patient has an underlying systemic disease such as rheumatoid arthritis or another rheumatic disorder, coordinated care between eye specialists and other medical professionals becomes essential.^[4]

Medical societies have established guidelines for treating ulcerative keratitis based on decades of clinical experience and research. These standard approaches form the foundation of care. However, the medical community continues to explore innovative therapies through clinical trials, searching for treatments that might work faster, cause fewer side effects, or help patients who don’t respond well to conventional medications. Quick recognition and prompt treatment are crucial, as delays can lead to permanent vision loss or, in cases linked to systemic autoimmune diseases, even mortality from complications affecting other organs.^[7]

Standard Medical Treatment Approaches

The cornerstone of treating ulcerative keratitis caused by autoimmune processes involves medications that suppress the immune system. These drugs work to stop the body from attacking its own corneal tissue. Methotrexate is one commonly prescribed medication that interferes with cell growth and immune responses. Doctors administer it either by mouth as pills or through injection into a vein, depending on the severity of the condition and how quickly they need the medication to work.^[1]

Cyclophosphamide represents a more powerful class of immune-suppressing drugs called alkylating agents. It works by damaging the DNA of rapidly dividing immune cells, thereby reducing the inflammatory attack on the cornea. While effective, this medication requires careful monitoring because it can affect blood cell production and has other significant side effects. Doctors typically reserve cyclophosphamide for severe cases or situations where other treatments have failed.^[4]

Newer medications called biologic agents have changed the treatment landscape significantly. Rituximab is a laboratory-made antibody that targets specific immune cells called B-lymphocytes. By depleting these cells, rituximab interrupts the chain of events leading to corneal inflammation. Etanercept works differently—it blocks a substance called tumor necrosis factor (TNF), which plays a central role in inflammation. Both medications are given by injection or infusion and have shown promise in managing difficult cases of peripheral ulcerative keratitis.^[1][7]

For immediate control of inflammation, doctors often start treatment with corticosteroids. Systemic steroids like oral prednisone or intravenous methylprednisolone work quickly to dampen immune responses throughout the body. Initial dosing may be quite high—sometimes 1 gram of methylprednisolone given over 30 minutes through an IV, or 1 milligram per kilogram of body weight daily for oral prednisone. These powerful medications reduce inflammation rapidly, buying time for slower-acting immune-suppressing drugs to take effect.^[13]

However, long-term steroid use brings its own set of problems. Extended courses can cause bone thinning, weight gain, elevated blood sugar, increased infection risk, and mood changes. For this reason, doctors work to transition patients to “steroid-sparing” medications—the immune suppressants mentioned earlier that can control disease without requiring ongoing high doses of corticosteroids. This transition typically happens gradually, with careful monitoring to ensure the disease remains controlled as steroid doses decrease.^[13]

Topical treatments applied directly to the eye surface also play an important role. Corticosteroid eye drops such as 0.1% dexamethasone or prednisolone acetate drops deliver anti-inflammatory medication right where it’s needed. In the early, acute phase of disease, doctors may prescribe these drops as frequently as every hour or two around the clock. The frequency gradually decreases as inflammation comes under control. However, topical steroids must be used judiciously in ulcerative keratitis because they can sometimes worsen corneal thinning by interfering with tissue repair.^[8][13]

To prevent secondary bacterial infections in an already compromised cornea, prophylactic antibiotics are standard care. Ciprofloxacin 0.3% drops, typically applied four times daily, provide broad-spectrum coverage against the bacteria most likely to invade damaged corneal tissue. Other antibiotics like moxifloxacin may be chosen based on individual circumstances. These are used even when there’s no evidence of infection, as prevention rather than treatment.^[13]

Oral medications that inhibit enzymes responsible for breaking down corneal collagen have shown benefit in some patients. Doxycycline, an antibiotic that also has anti-inflammatory properties, blocks certain matrix metalloproteinases—enzymes that digest the structural proteins in the cornea. By preventing this enzymatic breakdown, doxycycline can slow or halt the progressive thinning characteristic of ulcerative keratitis. Similarly, vitamin C supplementation promotes collagen synthesis, potentially supporting corneal repair processes.^[14]

Topical immunosuppressive agents offer another treatment avenue. Cyclosporine eye drops at 0.5% to 1% concentration, or tacrolimus 0.1% drops, work by inhibiting T-cells—immune cells involved in the inflammatory cascade. These medications can be particularly useful for managing Mooren ulcer, a form of ulcerative keratitis without systemic disease association. When used four times daily along with steroids and antibiotics, these drops may help control local inflammation while minimizing systemic side effects.^[13]

Treatment duration varies considerably based on the underlying cause and severity of disease. In autoimmune-related cases, initial intensive therapy may continue for several months. Once complete resolution of the ulcer occurs—meaning the epithelial defect heals and inflammation subsides—doctors typically maintain full-dose treatment for at least three months before beginning a slow taper. This extended treatment period helps prevent recurrence. Some patients with chronic underlying conditions may require ongoing maintenance therapy indefinitely.^[13]

Side effects from systemic immunosuppression can be significant. Methotrexate may cause liver problems, mouth sores, and sensitivity to sunlight. Cyclophosphamide can lead to bladder irritation, hair loss, and increased cancer risk with prolonged use. Biologic agents carry infection risks since they deliberately weaken immune defenses. Regular blood tests monitor liver and kidney function, blood cell counts, and other parameters. Patients need screening for latent tuberculosis before starting immunosuppression, as these drugs can reactivate dormant TB infection. Close collaboration between ophthalmologists, rheumatologists, and primary care doctors ensures safe medication management.^[12][17]

Surgical and Procedural Interventions

When the cornea becomes severely thin or medical therapy alone proves insufficient, surgical approaches become necessary. One technique involves applying tissue adhesive—a special medical-grade glue—to fill in areas of extreme thinning or small perforations. The doctor places this adhesive directly into the ulcer crater, then covers the area with a specialized therapeutic contact lens. This lens serves multiple purposes: it holds the adhesive in place, protects the fragile tissue, reduces pain, and helps control inflammation by acting as a bandage.^[1][4]

For larger areas of damage or when adhesive isn’t sufficient, surgeons may perform a partial thickness corneal transplant, also called a lamellar keratoplasty or patch graft. In this procedure, the surgeon removes the diseased, thinned area of peripheral cornea and replaces it with healthy donor corneal tissue. Unlike a full-thickness transplant, this procedure preserves the patient’s deeper corneal layers and inner eye structures. The graft provides structural support, preventing perforation while medical therapy works to control the underlying inflammation.^[1][4]

Some cases benefit from conjunctival resection—surgical removal of the inflamed conjunctival tissue adjacent to the ulcer. The blood vessels running through this tissue can transport inflammatory cells and immune complexes to the peripheral cornea, perpetuating damage. By excising this tissue and often covering the area with amniotic membrane—a biological material derived from human placenta—surgeons can reduce the inflammatory stimulus. Amniotic membrane has natural anti-inflammatory properties and provides a substrate for healing.^[6]

In a case documented by medical professionals, a patient who developed worsening corneal thinning underwent conjunctival resection with amniotic membrane grafting. The membrane was placed over a 9×6 millimeter epithelial defect. While the cornea remained thin initially, superficial blood vessels gradually grew into the thinned area, a process called neovascularization that can provide support and nutrients to aid healing. Combined with a transition from oral prednisone to methotrexate, this approach led to improvement in both the epithelial defect and corneal thinning.^[6]

Treatment in Clinical Trials and Emerging Therapies

While the sources provided don’t contain detailed information about specific clinical trials or experimental drugs currently being tested for ulcerative keratitis, some emerging treatment approaches are being explored. Research continues into optimizing existing biologic agents and developing new immunomodulatory therapies that might offer better disease control with fewer side effects.

Rituximab has gained particular attention in recent studies as potentially superior to older therapies. Case series examining treatment outcomes for peripheral ulcerative keratitis associated with granulomatosis with polyangiitis identified rituximab as having the highest success rate—63%—for achieving steroid-free remission. In comparison, cyclophosphamide, the traditional gold standard, achieved a 31% success rate. This suggests rituximab may become a preferred first-line agent for certain forms of ulcerative keratitis tied to vasculitis.^[13]

Recent reports describe successful treatment using combination biologic therapy. One case of rheumatoid arthritis-associated peripheral ulcerative keratitis achieved rapid healing using prednisolone, methotrexate, and adalimumab together. Adalimumab is another TNF-blocking biologic similar to etanercept. The rationale for combination therapy is that different medications target distinct points in the inflammatory cascade, potentially providing more complete immune control than any single agent alone.^[13]

Research into the biological mechanisms underlying ulcerative keratitis continues to identify new potential therapeutic targets. Scientists have discovered that the peripheral cornea’s unique anatomy—with direct blood supply extending 0.5 millimeters onto the corneal surface—creates an environment where inflammatory markers can easily reach corneal tissue. Understanding this helps researchers develop strategies to interrupt specific molecular pathways involved in inflammation and tissue destruction.^[6]

Topical nerve growth factor (NGF) represents another area of investigation. Some patients with corneal neurotrophic ulcers and corneal melting have been treated with topically applied NGF with reported success. This naturally occurring protein supports nerve cell survival and may promote healing of epithelial defects while reducing destructive processes in the cornea. While not yet widely available, it represents the type of innovative approach being explored.^[13]

Studies examining collagenase inhibitors offer another therapeutic direction. Besides doxycycline, researchers have investigated topical 20% N-acetylcysteine, which inhibits enzymes that break down collagen. By preserving the cornea’s structural proteins, these agents might slow or prevent the progression from ulceration to perforation. Though not necessarily new drug candidates, optimizing their use represents ongoing clinical research.^[7]

Most Common Treatment Methods

• Systemic Immunosuppression
  • Methotrexate administered orally or intravenously to suppress immune responses attacking corneal tissue
  • Cyclophosphamide for severe cases, working through DNA damage to immune cells
  • Oral prednisone or intravenous methylprednisolone for rapid inflammation control, typically at high doses initially
  • Gradual transition to steroid-sparing agents to minimize long-term corticosteroid side effects
• Biologic Therapy
  • Rituximab targeting B-lymphocytes through injection or infusion, showing 63% success for steroid-free remission in certain cases
  • Etanercept and adalimumab blocking tumor necrosis factor to reduce inflammation
  • Combination biologic therapy with traditional immunosuppressants for refractory cases
• Topical Medications
  • Corticosteroid drops (dexamethasone 0.1% or prednisolone acetate) applied hourly in acute phases, then tapered
  • Prophylactic antibiotic drops like ciprofloxacin 0.3% or moxifloxacin four times daily to prevent secondary infection
  • Cyclosporine 0.5-1% or tacrolimus 0.1% drops four times daily for local immune suppression
  • Preservative-free artificial tears for corneal surface support
• Oral Adjunctive Therapy
  • Doxycycline to inhibit matrix metalloproteinases that break down corneal collagen
  • Vitamin C supplementation to promote collagen synthesis and corneal repair
• Surgical Interventions
  • Tissue adhesive application with bandage contact lens for areas of severe thinning or small perforations
  • Partial thickness corneal transplant (lamellar keratoplasty) to replace diseased tissue with healthy donor cornea
  • Conjunctival resection to remove inflamed tissue adjacent to ulcers
  • Amniotic membrane grafting for its anti-inflammatory properties and healing support